EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Salvage Whole-Pelvic Radiation and Long-Term Androgen-Deprivation Therapy in the Management of High-Risk Prostate Cancer: Long-Term Update of the McGill 0913 Study

Sara Elakshar, Marwan Tolba iD, Steven Tisseverasinghe, Laurie Pruneau iD, Vanessa Di Lalla, Boris Bahoric, Tamim Niazi

Current Oncology · 2023

DOI: 10.3390/curroncol30080526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Sara Elakshar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiation Oncology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbvie pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To report the long-term outcomes of the McGill 0913 study and the potential benefits of combining prostate-bed radiotherapy (PBRT), pelvic-lymph-node radiotherapy (PLNRT), and long term ADT (LT-ADT). Materials and Methods: From 2010 to 2016, 46 high-risk prostate cancer patients who experienced biochemical recurrence (BCR) after radical prostatectomy (RP) were enrolled in this single-arm phase II clinical trial. The patients were eligible if they had a Gleason score > 8, locally advanced disease (≥pT3), a preoperative PSA of >20 ng/mL, or positive lymph nodes (LN). The patients were treated with a combination of 24 months of ADT, PBRT, and PLNRT. The primary outcome was biochemical progression-free survival (bPFS) and the predefined secondary endpoints included distant-metastasis-free survival (DMFS), overall survival (OS), and toxicity. In this update, we also report the median follow-up of 8.8 years and 10 years OS.

Results

At a median follow-up of 8.8 years, 43 patients were eligible for analysis. The median pre-salvage PSA was 0.30 μg/L. Half (51%) of the patients (n = 22) had positive margins, 40% (n = 17) had Gleason scores > 8, 63% (n = 27) had extracapsular extension, 42% (n = 18) had seminal vesicle invasion, and 19% (n = 8) had LN involvement. The 10-year bPFS was 68.3 %. The 10-year DMFS was 72.9%. The 10-year OS was 97%. There were two non-cancer-related deaths. The first patient died of congestive heart failure while the other died of an unknown cause. No new toxicity was observed after the initial report.

Conclusions

Our study demonstrates that treatment escalation with PBRT, PLNRT, and LT-ADT improves long term outcomes. In view of the recently published SPPORT study, we conclude that this novel approach of treatment intensification in high-risk post-prostatectomy patients is safe and effective, and that it should be offered as the standard of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiation OncologyMaleHumansAndrogen AntagonistsAndrogensProstate-Specific Antigen

Stichwörter der Autor:innen

cancerhormonal therapyprostateradical prostatectomyradiotherapysalvage

Substanzen

Androgen AntagonistsAndrogensProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiation Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
  • Department of Clinical Oncology, Tanta University Hospitals, Tanta University, Tanta 6632110, Egypt.
  • Department of Radiation Oncology, Gatineau Hospital, McGill University, Gatineau, QC J8P 7H2, Canada.

ORCID-Profile: Marwan Tolba, Laurie Pruneau

Förderung

  • Abbvie pharmaceuticals

Zitieren

APA

Elakshar, S., Tolba, M., Tisseverasinghe, S., Pruneau, L., Di Lalla, V., Bahoric, B., & Niazi, T. (2023). Salvage Whole-Pelvic Radiation and Long-Term Androgen-Deprivation Therapy in the Management of High-Risk Prostate Cancer: Long-Term Update of the McGill 0913 Study. Current Oncology. https://doi.org/10.3390/curroncol30080526

Vancouver

Elakshar S, Tolba M, Tisseverasinghe S, Pruneau L, Di Lalla V, Bahoric B, et al. Salvage Whole-Pelvic Radiation and Long-Term Androgen-Deprivation Therapy in the Management of High-Risk Prostate Cancer: Long-Term Update of the McGill 0913 Study. Current Oncology. 2023. doi:10.3390/curroncol30080526

BibTeX
@article{Elakshar2023,
  author = {Elakshar, Sara and Tolba, Marwan and Tisseverasinghe, Steven and Pruneau, Laurie and Di Lalla, Vanessa and Bahoric, Boris and Niazi, Tamim},
  title = {Salvage Whole-Pelvic Radiation and Long-Term Androgen-Deprivation Therapy in the Management of High-Risk Prostate Cancer: Long-Term Update of the McGill 0913 Study},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30080526}
}
Kostenlos starten →